ALSO NOTED: Big Biotech emerges as a shelter in economic storm; Arseus recalls compounded heparin;

> While just about every category of stocks has been hammered in recent months, biotech has edged up. Investors have been betting that the biotech business model, which relies on breakthrough technologies and long-term contracts, could well weather the economic storm in the U.S. Report

> Belgian healthcare group Arseus saw trading in its shares suspended today after it revealed that its pharma compounding division had been supplying contaminated heparin to Dutch hospitals. The company said it had recalled the contaminated meds immediately, and hospitals destroyed their stocks before any was given to patients. Report

> Eli Lilly's Alimta drug got the E.U. nod as a first-line treatment for non-small cell lung cancer. Report

> Opposition MPs accused the Conservative Canadian government of changing the Drugs and Food Act to allow the cabinet to usher in DTC advertising without permission from Parliament. Report

> Laureate Pharma inked a deal to manufacture Alopexx's anti-staph treatment; terms of the contract weren't disclosed. Report

> Sir Christopher Evans' is scrapping Merlin Biosciences and transferring the early-stage venture funds to the newly-formed Excalibur, which will shift focus to late-stage therapies. Report

> Everyone involved in embryonic stem cell programs will be paying close attention to hearings the FDA is holding on how they plan to regulate the field. Report

And Finally... A diabetes drug could turn out to be an effective epilepsy treatment. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.